A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment
NCT05376839
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
INDUSTRY
Sponsor class
Stopped
Strategic considerations
Conditions
Hepatic Impairment
Interventions
DRUG:
Cedirogant
Sponsor
AbbVie